Karl is co-founder of Aglaia BioMedical Ventures. He holds an MBA from the University of Georgia (USA), following his studies at The Netherlands School of Business, Nyenrode. Already before starting Aglaia, he had been involved in the founding, restructuring and funding of multiple technology-driven companies. Within Aglaia he covers legal and finance. He serves on the board of a number of life sciences companies.
InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
MIMETAS Secures 20 Million Dollar Series B Financing